Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. by Urien, Saik et al.
Anakinra pharmacokinetics in children and adolescents
with systemic-onset juvenile idiopathic arthritis and
autoinflammatory syndromes.
Saik Urien, Christophe Bardin, Brigitte Bader-Meunier, Richard Mouy,
Sandrine Compeyrot-Lacassagne, Franz Foissac, Benoˆıt Florkin, Carine
Wouters, Be´ne´dicte Neven, Jean-Marc Treluyer, et al.
To cite this version:
Saik Urien, Christophe Bardin, Brigitte Bader-Meunier, Richard Mouy, Sandrine Compeyrot-
Lacassagne, et al.. Anakinra pharmacokinetics in children and adolescents with systemic-onset
juvenile idiopathic arthritis and autoinflammatory syndromes.. BMC Pharmacology and Toxi-
cology, BioMed Central, 2013, 14 (1), pp.40. <10.1186/2050-6511-14-40>. <inserm-00850983>
HAL Id: inserm-00850983
http://www.hal.inserm.fr/inserm-00850983
Submitted on 10 Aug 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH ARTICLE Open Access
Anakinra pharmacokinetics in children and
adolescents with systemic-onset juvenile
idiopathic arthritis and autoinflammatory
syndromes
Saik Urien1,2*, Christophe Bardin3, Brigitte Bader-Meunier2,4, Richard Mouy4, Sandrine Compeyrot-Lacassagne4,
Franz Foissac1,2, Benoît Florkin4, Carine Wouters4, Bénédicte Neven2,4, Jean-Marc Treluyer1,2,3†
and Pierre Quartier2,4†
Abstract
Background: Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents
treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes.
Methods: Anakinra was given subcutaneously at doses between 2 and 10 mg/kg (maximum 100 mg) per day.
Anakinra concentrations were recorded in patients, as well as C-reactive protein (CRP) levels, on different occasions.
The data were fitted to a pharmacokinetic-pharmacodynamic model via a population approach using Monolix.
Results: A total of 87 children and adolescents, 8 months to 21 years old, were available for pharmacokinetic
evaluation. A one compartment model with linear absorption and elimination described the pharmacokinetics.
Taking into account bodyweight to explain variations in apparent clearance (CL/F) and distribution volume (V/F)
significantly reduced the associated between-subject and between-occasion variabilities. The final estimates were
6.24 L/h/70 kg and 65.2 L/70 kg for CL/F and V/F respectively. A mixture pharmacodynamic model described the
CRP level change during anakinra treatment for the SJIA patients with 2 subpopulations, patients with high baseline
and large CRP decrease and patients with low baseline and small CRP decrease followed by a re-increase in CRP
levels. There was no significant effect of the combined anti-inflammatory treatment. The proportion of patients for
which the development of a resistance to treatment was significant was 62% and the corresponding time was
approximately 60 days.
Conclusions: Based on effects in SJIA, a prospective dosage adjustment was proposed based on a 0.4 mg/L Css
target in order to obtain a CRP decrease to 10 mg/L or below.
Background
Anakinra, a recombinant nonglycosylated homolog of hu-
man IL-1 receptor antagonist, competitively inhibits the
binding of IL-1α and IL-1β to the IL-1 receptor and thus
inhibits the effects of this pro-inflammatory cytokine. Il-1
blockade using selective IL-1β blockade (canakinumab) or
IL-1 α and β blockade (anakinra, rilonacept) has proven ef-
ficacy in cryopyrin-associated periodic syndromes (CAPS)
[1] and more recently in systemic-onset juvenile idiopathic
arthritis (SJIA) [2-5]. In patients with CAPS, anakinra has
been shown to induce clinical remission in most cases,
decrease the inflammatory markers including C-reactive
protein (CRP) and improve patient’s quality of life on the
long term [1,6]. In the first randomized placebo-controlled
trial published with anakinra in SJAI, the number of active
joints, CRP and the physician global disease activity assess-
ment using a visual analalog scale (VAS) were signifi-
cantly decreased in the anakinra group compared to the
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placebo group at one month. However, some patients
eventually experienced a disease flare and the authors
hypothesised that suboptimal anakinra dosage might
be partly responsible for a lack of sustained efficacy, in
low-weight children [3].
The aim of the present study was to investigate anakinra
pharmacokinetics in children and young adult patients
with SJIA and autoinflammatory conditions. The effects of
anakinra on CRP was also modelled in relation to the
anakinra pharmacokinetics in children with SJIA.
Methods
Patients
Following IRB (CPP Paris V) approval and patients and/or
parents (for children) written informed consent, pharma-
cokinetic data were obtained from a phase IIB trial testing
anakinra in SJIA patients (ANAJIS)(5) and from patients
subsequently treated for diverse autoinflammatory condi-
tions. In ANAJIS trial all the patients received anakinra
once-a-day at the dose of 2 mg/kg subcutaneously, max-
imum 100 mg. In patients with autoinflammatory syn-
dromes treated afterwards, anakinra was given at doses
ranging between 2 and 10 mg/kg daily (the highest doses
were in low-weight CAPS patients who had failed to re-
spond to lower doses). In the patients who took part to
ANAJIS trial, CRP was recorded at each visit and retained
for the pharmacodynamic modeling.
Anakinra plasma determination
Anakinra plasma determinations were performed on blood
taken at one or repeated occasions depending on the study
group. Whole blood samples were collected into tubes
containing heparin. Plasma was separated immediatly after
sampling and frozen at −20°C. Concentrations of anakinra
in plasma samples were determined using the antibody
(Ab) ELISA purchased from R&D Systems (Minneapolis,
Minnesota, USA). Briefly, samples and quality controls
were diluted with buffered animal serum and added to a
microtiter plate which have been pre-coated with a
monoclonal antibody specific for IL-1ra. An enzyme-
linked polyclonal antibody specific for IL-1ra (horseadish
peroxydase) was added to the wells. Following a wash, a
substrate solution was added for color development. Re-
action was stopped with sulfuric acid. Optical density
was determined using a microplate reader set to 450 nm.
Anakinra concentration were calculated for each sample
by log-log curve fitting of the plate standards dilutions.
The lower limit of quantification (LOQ) for anakinra
concentrations in plasma samples was 40 ng/mL.
Pharmacokinetic modelling
Pharmacokinetic data was ascribed to an open one-or two-
compartment models with linear absorption. Zero-order
absorption and absorption with transit compartments
models, as well as the possibility of non-linear elim-
ination, were also considered.
Pharmacodynamic modelling
The CRP levels as a function of time and drug treatment
were ascribed to a indirect response model. In this model,
anakinra is thought to inhibit the response production rate,
kTR*R0 (transit time rate constant multiplied by response
at baseline). The model equation was then
dR=dt ¼ kTR  R0  1−C= C50 þ Cð Þ½ −kTR  R ð1Þ
where R, C50 and C stand for the pharmacodynamic re-
sponse, 50% inhibitor concentration and drug concentra-
tion. When the drug treatment starts, the system is at
equilibrium (stable disease) what is defined by the baseline
parameter, R = R0.
Some individual time-courses showed that there was a
loss of drug effect during the treatment time. To take
this into account, an empirical resistance function was
as a function of time was defined
Resis ¼ exp −kRESItð Þ
where kRESI is a time rate constant of resistance appear-
ance. Then the response model becomes
dR=dt ¼ kTR  R0  1–Resis C= C50 þ Cð Þ½  − kTR  R
ð2Þ
Therefore, using a mixture model, the patients were as-
cribed to either equation (1) or (2). The CRP levels were
analysed in the 22 SJIA patients from the ANAJIS trial.
Population pharmacokinetic and pharmacodynamic
analysis
Pharmacokinetic and pharmacodynamic data were ana-
lysed using the nonlinear mixed effect modelling soft-
ware program Monolix version 3.2 (http://www.lixoft.
com/) [7]. Pharmacodynamic data were obtained from
the 22 ANAJIS trial patients: the CRP concentrations
were log10–transformed to take into account the wide
range of observed data during the analysis. The data were
analysed sequentially; the pharmacokinetic estimates
were fixed for the pharmacodynamic analysis. Param-
eters were estimated by computing the maximum
likelihood estimator of the parameters without any
approximation of the model (no linearization) using the
stochastic approximation expectation maximization
(SAEM) algorithm combined to a MCMC (Markov
Chain Monte Carlo) procedure. The number of MCMC
chains was allowed to vary in order to obtain a nice and
reliable convergence of the SAEM algorithm. Additive
and proportional error models were used to describe the
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residual variability (ε) for the pharmacokinetic and phar-
macodynamic data respectively, and the between-subject
or between occasion variabilities (η or φ) were generally
ascribed to an exponential model, except specific indica-
tion. The likelihood ratio test (LRT) including the log-
likelihood, the Akaike information criterion (AIC) and
the bayesian information criterion (BIC) was used to test
different hypotheses regarding the final model, covariate
effect on structural parameter(s), residual variability
model (proportional versus proportional plus additive
error model), structure of the variance-covariance matrix
for the BSV parameters. The normalised prediction dis-
tribution errors (NPDE) metrics [8] were used used as a
main diagnostic tool to evaluate the final model and were
directly computed by Monolix. Diagnostic graphics and
other statistics were obtained by using RfN (http://wfn.
sourceforge.net/) with the R program [9].
Results
Population pharmacokinetic modeling
A total of 87 children (32 girls, 52 boys) with 148 anakinra
concentrations were available for pharmacokinetic evalu-
ation, four concentrations were observed below the limit of
quantification (BLQ) and coded as left censored data for
the analysis. The distribution of sampling times can be ob-
served in Figure 1.
The 22 SJIA patients were 2.26 – 16.8 years old
(median 7.6) weighing 10 – 83 kg (median 21). The
other patients were 0.73 – 21 years old (median 8)
weighing 4.3 – 60 kg (median 21). These included 20
patients with CAPS (14 with the chronic, inflamma-
tory, neurologic, cutaneous and articular (CINCA)
syndrome / neonatal onset multisystem inflammatory
disease (NOMID) and 6 with Muckle-Wells syndrome),
mevalonate kinase deficiency (n = 3), TNF-receptor asso-
ciated periodic syndromes (n = 2), familial mediterranean
fever (n = 1) and patients with genetically undetermined
autoinflammatory conditions.
A one-compartment with linear absorption and elim-
ination model adequately described the data. Other
candidate models included one-compartment with non-
linear elimination and two-compartment models. The
parameters of the model were Ka, V/F and CL/F, re-
spectively the absorption rate, the apparent volume of
distribution and clearance, F being the unknown bio-
availability. The statistical model included a between-
subject variability for CL/F, ηCL, and a between-occasion
variability for V/F, γV/F. The residual variability was de-
scribed as an additive component.
The only covariates that influenced the pharmacoki-
netic parameters were age and bodyweight (BW). CL/F
and V/F were then related to BW using an allometric
function with estimated power exponents. This de-
creased the CL/F and V/F variabilities from 0.41 to 0.28
and from 1.34 to 0.475 and the AIC and BIC criteria by
more than 15 units. This BW effect finally removed the
effect of age. No other covariate effect could be identi-
fied, gender or combined use of corticoids or anti-
inflammatory drugs, AINS. The final models for CL/F
and V/F were then
CL=F ¼ 0:847 BW0:47
V=F ¼ 2:581 BW0:76
Figure 1 depicts anakinra observed time-courses and
the median and 5th/95th percentiles of the model predic-
tions. Table 1 summarises the final population pharma-
cokinetic estimates. As shown, all parameters were well
estimated with low relative standard errors.
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Figure 1 Anakinra concentration-time courses for once daily
administrations. Solid and dashed lines, median and 5th/95th
percentiles of the final model predictions.
Table 1 Parameter estimates of the final anakinra
population pharmacokinetic model in 87 pediatric
patients
Parameter Estimate Relative standard error (%)
CL/F (L h-1 70 kg-1) 6.24 8
βCL, TV(CL)∙(BW/70)
βCL 0.47 14
V/F (L) 65.2 12
βV, TV(V)∙(BW/70)
βV 0.76 16
Ka (h-1) 0.38 19
ηCL/F 0.28 15
γV/F 0.47 17
ε, mg/L 0.072 10
Key: CL/F, apparent elimination clearance; V/F, apparent volume of distribution;
Ka, absorption rate constant; F, unknown bioavailability; TV(), typical value for
the mean covariate value; β, covariate effect parameter; η, between-subject
variability; γ, between occasion variability; ε, constant residual variability; BW,
bodyweight (CL/F and V/F estimates are normalized to a 70 kg BW).
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Pharmacodynamic modeling
An indirect response model assuming that the produc-
tion rate of the inflammatory process is inhibited by
anakinra concentrations described well the CRP time-
courses in the 22 ANAJIS trial patients (195 observa-
tions were available). The C50 parameter was related to
the mean steady-state anakinra concentration (Css),
allowing the determination of the corresponding dosage
to obtain for example 90% of the maximal effect (C90 ~
10 x C50), i.e., dose rate (mg/h) = CL/F*C90. A mixture
model with 2 subpopulations, patients with high baseline
and large CRP decrease and patients with low baseline
and small CRP decrease followed by a slow re-increase
in baseline levels (delayed “resistance” to treatment), was
finally retained. The corresponding observed baselines
(median [range]), 120 [44, 230] and 43 [2.5, 152] mg/L,
were significantly different (p = 0.02, Kruskal-Wallis test).
However it was impossible to estimate a clear cut-off
value between the 2 groups, probably because of the
small sample size. There was no significant effect of the
combined anti-inflammatory treatment. The proportion
of patients for which the development of a “resistance”
to treatment was significant was 62% and the corre-
sponding time was approximately 60 days. Table 2 sum-
marizes the results and Figure 2 depicts the CRP
observed time-courses and the median and 5th/95th per-
centiles of the model predictions.
Evaluation and validation
Figures 1 and 2 show that the average prediction matches
the observed concentrations or CRP time courses and
that the variability is reasonably estimated. Moreover,
the NPDE residuals corresponding to these modellings also
validated these population models, the mean and variance
were not significantly different from 0 and 1 and the distri-
bution did not differ from normality.
Dosage simulations
Figure 3 shows the model-predicted CRP time-courses
for different Css values. Clearly, the target Css is 0.4 mg/L
in order to obtain a CRP decrease to 10 mg/L or below.
Accordingly, the anakinra dosage as a function of body-
weight can be deduced as shown in Figure 4.
Discussion
This is the first pharmacokinetic study of anakinra in
children. In pediatric patients with SJIA and diverse
autoinflammatory conditions, the pharmacokinetics of
anakinra following sub-cutaneous administration was
Table 2 Parameter estimates of the anakinra effect on
c-reactive protein concentrations in 22 SJIA patients
(RESP = responders and RESI = patients with onset of
“resistance” to treatment)
Parameter Estimate Relative standard error (%)
Baseline (mg/L)
RESP 141 27
RESI 37.9 29
kTR (day
-1) 0.042 27
C50 (mg/L) 0.03 37
kRESI (day
-1) 0.0048 0.0018
Proportion of RESP 0.37 31
ηBASELINE.RESI 0.79 24
ηKTR 081 25
ε, mg/L (*) 0.39 6
Key: Baseline, CRP level before treatment; kTR, transit time rate constant;
C50, anakinra concentration that induces a 50% decrease of CRP level;
kRESI, time rate constant of resistance appearance; η, between-subject
variability; ε, constant residual variability, *log-additive model.
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Figure 2 Effect of anakinra on the C-reactive concentration-time
courses during the ANAJIS trial. The top and bottom plots stand for
the 2 response groups : top, responders; bottom, patients with a
delayed “resistance” to treatment. Solid and dashed lines, median and
5th/95th percentiles of the final model predictions.
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satisfactorily described by a one compartment model
with 1st order absorption. Bodyweight was identified as
the sole significant covariate that could finally explain a
significant part of the variability and this BW effect was
modeled via an allometric scaling of CL/F and V/F. The
allometric power values are typically 1 and 0.75 for BW
effect on V and CL respectively [10]. Because our esti-
mates were not so close to these theoretical values and
because anakinra is a 153 amino acids peptide chain and
somewhat different from standard drugs, the estimated
power effects were retained in the final pharmacokinetic
model. The improvement of the predictive performance
of the model (observed vs. predicted data, not shown) as
well as a decrease in the CL/F and V/F variabilities vali-
dated this model.
Assuming that anakinra inhibits the production of the
inflammatory marker CRP via an “Emax” model allowed
a satisfactory description of the CRP time-course during
anakinra treatment in SJIA patients. As seen in Figure 2,
this was monitored and modelled up to approxi-
mately 400 days of treatment. The C50 estimate was
low (0.03 mg/L) and nearly all the observed concentra-
tions were above this limit. According to the pre-
dicted time-course effects of different mean Css values
(Figure 3), a Css value of 0.4 mg/L was retained to ob-
tain the maximal effect. The dosages per 24 h that pro-
duce this 0.4 mg/L Css are depicted in Figure 4.
Therefore, the actual dosage of 2 mg/kg/day in SJIA
patients was appropriate in the 10 – 50 kg BW range
children, but not in low weight or early age children,
BW < 10 kg, for which the efficient mean dose would be
3 mg/kg/day. Also, the oldest chilgren, > 50 kg BW, could
have received a flat dose of 100 mg/day, similar to the
adult dosage.
Conclusions
Bodyweight significantly influenced the pharmacokinet-
ics of anakinra. An allometric BW scaling of apparent
clearance and distribution volume was sufficient to
describe the variation of anakinra pharmacokinetics in
these 87 pediatric patients weighing from 4 to 80 kg and
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Figure 3 Model-predicted effect of anakinra on the C-reactive concentration-time courses assuming 0.02 to 0.40 mg/L mean steady-state
anakinra concentrations in the 2 subgroups of patients. Left, high base level with large CRP decrease. right, moderate base CRP with initial decrease
followed by a re-increase in CRP concentrations.
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9 months to 21 years old. The effect on the C-reactive pro-
tein was adequately described by a turn-over model and
allowed to derive some concentration-dose guidelines for
SJIA disease.
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